VCEL

SEC source: 0001140361-26-018544 · form4.xml · derivative · entry 3

MCLAUGHLIN KEVIN F · CIK 0001214938 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2036-04-29

F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001140361-26-018544 · form4.xml · derivative · entry 2

MCLAUGHLIN KEVIN F · CIK 0001214938 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018544 · form4.xml · nonDerivative · entry 1

MCLAUGHLIN KEVIN F · CIK 0001214938 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.

SEC source: 0001140361-26-018543 · form4.xml · derivative · entry 4

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,200

Underlying: Common Stock · 3,200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018543 · form4.xml · derivative · entry 3

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2036-04-29

F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001140361-26-018543 · form4.xml · derivative · entry 2

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018543 · form4.xml · nonDerivative · entry 1

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.

SEC source: 0001140361-26-018539 · form4.xml · derivative · entry 4

WRIGHT LISA · CIK 0001865017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,200

Underlying: Common Stock · 3,200 shares

Expires not disclosed

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F7 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018539 · form4.xml · derivative · entry 3

WRIGHT LISA · CIK 0001865017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2036-04-29

F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001140361-26-018539 · form4.xml · derivative · entry 2

WRIGHT LISA · CIK 0001865017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 30, 2025, the Reporting Person deferred the receipt of 3,200 shares of Common Stock and instead received 3,200 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F4 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018539 · form4.xml · nonDerivative · entry 1

WRIGHT LISA · CIK 0001865017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Restricted Stock Units (RSUs) converted to Phantom Stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.

F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 30, 2025, the Reporting Person deferred the receipt of 3,200 shares of Common Stock and instead received 3,200 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

SEC source: 0001140361-26-018540 · form4.xml · derivative · entry 4

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,200

Underlying: Common Stock · 3,200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018540 · form4.xml · derivative · entry 3

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2036-04-29

F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001140361-26-018540 · form4.xml · derivative · entry 2

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018540 · form4.xml · nonDerivative · entry 1

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.

SEC source: 0001140361-26-018542 · form4.xml · derivative · entry 4

Wotton Paul K · CIK 0001300997 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,200

Underlying: Common Stock · 3,200 shares

Expires not disclosed

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F7 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018542 · form4.xml · derivative · entry 3

Wotton Paul K · CIK 0001300997 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2036-04-29

F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001140361-26-018542 · form4.xml · derivative · entry 2

Wotton Paul K · CIK 0001300997 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 30, 2025, the Reporting Person deferred the receipt of 3,200 shares of Common Stock and instead received 3,200 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F4 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018542 · form4.xml · nonDerivative · entry 1

Wotton Paul K · CIK 0001300997 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Restricted Stock Units (RSUs) converted to Phantom Stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.

F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 30, 2025, the Reporting Person deferred the receipt of 3,200 shares of Common Stock and instead received 3,200 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

SEC source: 0001140361-26-018541 · form4.xml · derivative · entry 4

ZERBE ROBERT L MD · CIK 0001220363 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,200

Underlying: Common Stock · 3,200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018541 · form4.xml · derivative · entry 3

ZERBE ROBERT L MD · CIK 0001220363 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2036-04-29

F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001140361-26-018541 · form4.xml · derivative · entry 2

ZERBE ROBERT L MD · CIK 0001220363 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-018541 · form4.xml · nonDerivative · entry 1

ZERBE ROBERT L MD · CIK 0001220363 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.

SEC source: 0001140361-26-013334 · form4.xml · derivative · entry 3

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,132

Underlying: Common Stock · 3,472 shares

Expires 2028-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.

SEC source: 0001140361-26-013334 · form4.xml · nonDerivative · entry 2

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,556

F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.

F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-013334 · form4.xml · nonDerivative · entry 1

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,028

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-011730 · form4.xml · derivative · entry 2

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on May 4, 2016, becoming exercisable in equal monthly installments from June 4, 2016 through May 4, 2017, contingent upon continued service to the Company.

F3 · derivative.expiration_date: These options, which were awarded on May 4, 2016, would otherwise expire and become forfeitable on May 4, 2026.

SEC source: 0001140361-26-011730 · form4.xml · nonDerivative · entry 1

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time.

SEC source: 0001140361-26-011091 · form4.xml · derivative · entry 3

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

F3 · derivative.expiration_date: These options, which were awarded on May 4, 2016, would otherwise expire and become forfeitable on May 4, 2026.

SEC source: 0001140361-26-011091 · form4.xml · nonDerivative · entry 2

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,850

F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

SEC source: 0001140361-26-011091 · form4.xml · nonDerivative · entry 1

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-26-007855 · form4.xml · derivative · entry 4

Flynn Sean C. · CIK 0001801993 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 15,000 shares

Expires 2029-11-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These options, representing the right to purchase 150,000 shares, became exercisable on November 4, 2020, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.

SEC source: 0001140361-26-007855 · form4.xml · nonDerivative · entry 3

Flynn Sean C. · CIK 0001801993 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,262

F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2025.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-007855 · form4.xml · nonDerivative · entry 2

Flynn Sean C. · CIK 0001801993 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-007855 · form4.xml · nonDerivative · entry 1

Flynn Sean C. · CIK 0001801993 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,262

F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2025.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-007853 · form4.xml · nonDerivative · entry 1

Halpin Michael · CIK 0001778858 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,080

F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2025.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006974 · form4.xml · derivative · entry 5

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,750

Underlying: Common Stock · 18,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F8 · price: The Fair Market Value of the vested derivative securities is $38.09 per share.

F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.

F7 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-006974 · form4.xml · derivative · entry 4

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,500

Underlying: Common Stock · 18,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F7 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-006974 · form4.xml · nonDerivative · entry 3

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312,446

F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006974 · form4.xml · nonDerivative · entry 2

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 321,270

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006974 · form4.xml · nonDerivative · entry 1

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006973 · form4.xml · derivative · entry 10

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 1,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F11 · price: The Fair Market Value of the vested derivative securities is $38.25 per share.

F7 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively.

F9 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-006973 · form4.xml · derivative · entry 9

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 1,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F6 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F9 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-006973 · form4.xml · derivative · entry 8

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Common Stock · 3,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F10 · price: The Fair Market Value of the vested derivative securities is $38.09 per share.

F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.

F9 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-006973 · form4.xml · derivative · entry 7

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,650

Underlying: Common Stock · 350 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F9 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 6

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,556

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 5

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,192

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively.

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 4

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.

F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 3

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,192

F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-26-006973 · form4.xml · nonDerivative · entry 2

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,527

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.

F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).